Novo Nordisk Shares Plunge on Insulin's FDA Failure

Novo Nordisk Shares Plunge on Insulin's FDA Failure Play

Feb. 11 (Bloomberg) -- Bloomberg's Caroline Hyde reports that Novo Nordisk shares have fallen the most in a decade as the company's new insulin drug Tresiba has failed to win FDA approval in the United States. She speaks on Bloomberg Television's "The Pulse."

  • On Air Now

    Money Clip Watch Now

  • Next

    Bloomberg West

blog comments powered by Disqus